• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov14
Douglas Tsao Maintains Hold Rating on Outlook Therapeutics
23:41
Sep29
Outlook Therapeutics Completes Type A Meeting with FDA
13:37
Aug15
Outlook Therapeutics released FY2025 Q3 earnings on August 14 (EST), actual revenue USD 1.505 M (forecast USD 1.663 M), actual EPS USD -0.5499 (forecast USD -0.3525)
03:00
Outlook Therapeutics released FY2025 9 Months Earnings on August 14 EST, with actual revenue of USD 1.505 M and EPS of USD -1.3343
03:00
Jul1
Outlook Therapeutics Appoints Bob Jahr as CEO
12:06
Jun2
Outlook Therapeutics Launches First Bevacizumab Ophthalmic Formulation in Germany and the UK
11:44

Schedules & Filings

Schedules
Filings
Aug14
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 1.505 M, Net Income -20.15 M, EPS -0.5499

May15
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Net Income -46.36 M, EPS -1.5014

Feb14
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Net Income 17.38 M, EPS 0.717

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
LAZR
0.6044
+174.73%
+0.384
NBY
5.300
+79.66%
+2.350
MIMI
0.4795
+75.45%
+0.206
AZI
2.500
+64.47%
+0.980
GDC
5.260
+51.59%
+1.790
SOS
2.200
+47.65%
+0.710
IBO
0.6491
+46.26%
+0.205
FLYT
17.130
+45.42%
+5.350
CRWG
3.950
+45.22%
+1.230
CRWU
7.290
+44.93%
+2.260
View More